LONA LeonaBio, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$8.22

Period return

+4.34 (+111.86%)

Volume

16.0K

2026-06-05O $8.62 H $8.74 L $8.19 C $8.22MA5 $8.75MA20 $9.77MA60 $9.51MA120 $7.65

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 27.MediumBUY10 days ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 02. 19.MediumBUY4 months ago
Mizuho: Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $18 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Sector: Healthcare
Industry: Biotechnology
HQ: Bothell, WA, United States
Fiscal year end: —
Employees: 19
IPO date: —

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 27.	Piper Sandler	—	Initiate coverage	— → Overweight	—	Piper Sandler: Overweight
2026. 02. 19.	Mizuho	—	Upgrade	Neutral → Outperform	—	Mizuho: Neutral → Outperform

LeonaBio, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats